TitAIN Study: Secukinumab Efficacy in Giant Cell Arteritis A phase 2 trial has demonstrated the efficacy of secukinumab, an anti-interleukin-17A monoclonal antibody, in patients with active giant cell arteritis (GCA). https://t.co/rmYBXBV3RP https://t.co/q1CfhuGSj7